ibr854
Cell therapyexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2023 (NCT06001684)
Timeline
Indications
Mechanism of action
- Trophoblast glycoproteinImmunity, passive
immunity, passive - 5T4
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07087158 | Phase 2 | Aug 10, 2025 | Imbioray (Hangzhou) Biomedicine Co., Ltd. |
| NCT06001684 | Phase 1 | Sep 1, 2023 | Chinese Academy of Medical Sciences, Imbioray (Hangzhou) Biomedicine Co., Ltd. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Imbioray (Hangzhou) Biomedicine Co., Ltd. | For profit | 2 | 2 | 2 | 2023 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 0 | 1 | 2023 |
2 organizations
Page 1 / 1